Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, and efficacy of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). GLPG5101 is an autologous CD19 CAR-T cell therapy product candidate produc ...

georgeclerk Summary We maintain our Hold rating on Canadian Apartment Properties Real Estate Investment Trust (TSX:CAR.UN:CA / OTC:CDPYF). While operational performance has remained solid, we believe there are far more attractive risk/return profiles within Canadian residential REITs, such as Northview Residential REIT. The current price's proximity to our NAV estimate leads us to believe that unit performance over the short term should follow NOI and FFO growth (i.e., sector performance). We need to se ...

HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has been awarded a $2 million grant from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program to support the clinical investigation of MT-601 in patients with non-Hodgkin’ ...

Avis Budget Group, Inc. (CAR) reported lower-than-expected second-quarter 2024 results.The stock has increased 6.3% since its earnings release on Aug 5 despite the earnings and revenue miss.CAR’s earnings of 41 cents per share missed the Zacks Consensus Estimate by 84.2% and decreased 96.3% from the year-ago quarter’s actual. Total revenues of $3 billion missed the consensus estimate by 4% and decreased 2.4% on a year-over-year basis.Avis Budget’s shares have declined 47% in the past six months compared wit ...

Avis Budget Group, Inc. (NASDAQ:CAR) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants David Calabria - Senior Vice President, Corporate Finance and Treasurer Joseph Ferraro - President and Chief Executive Officer Izzy Martins - Executive Vice President and Chief Financial Officer Conference Call Participants Chris Woronka - Deutsche Bank Ryan Brinkman - JPMorgan John Babcock - Bank of America Lizzie Dove - Goldman Sachs Stephanie Moore - Jefferies Operator Greetings. Welcome t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File No. 001-10308 Avis Budget Group, Inc. (Exact name of registrant as specified in its charter) Delaware 06-0918165 (State o ...

Avis Budget Group Reports Second Quarter Results PARSIPPANY, N.J., August 5, 2024 - Avis Budget Group, Inc. (NASDAQ: CAR) announced financial results for second quarter 2024 today. We ended the quarter with revenues of more than $3.0 billion, driven by sequential monthly improvement in revenue per day. Net income was $15 million and our Adjusted EBITDA was $214 million. 1 "As the second quarter progressed, demand elevated with pricing and vehicle utilization sequentially improving. June pricing finished dow ...

Avis Budget Group, Inc. CAR is set to release earnings results for its second quarter, after the closing bell on Aug. 5, 2024.Analysts expect the Parsippany, New Jersey-based company to report quarterly earnings at $2.58 per share, down from $11.01 per share in the year-ago period. Avis Budget is projected to report quarterly revenue of $3.14 billion, according to data from Benzinga Pro.On May 14, Avis Budget Group announced the pricing of €200 million of senior notes.Avis Budget shares fell 10.7% to close ...

SAN JOSE, Calif., July 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on its ovarian cancer CAR-T therapy clinical trial at the International Gynecologic Cancer Society (IGCS) 2024 Annual Global Meeting being held October 16-18, 2024, in Dublin, Ireland.The presentation, titled "Phase I Clinical Trial of Autologous T-cells Genetically Engineered with a Chimer ...

LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Nexcella an $8 million CLIN2 grant award to support clinical development of its chimeric antigen receptor T cell (CAR-T) therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis. “AL amylo ...